» Articles » PMID: 8058153

Adjuvant Therapy with Dibromodulcitol and BCNU Increases Survival of Adults with Malignant Gliomas. EORTC Brain Tumor Group

Overview
Journal Neurology
Specialty Neurology
Date 1994 Aug 1
PMID 8058153
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: We tested adjuvant chemotherapy combining dibromodulcitol (DBD) and bischloroethylnitrosourea (BCNU) given postoperatively to adults with newly diagnosed supratentorial malignant gliomas.

Methods: We enrolled 269 patients, 255 of whom were eligible. After surgery, we treated all patients with radiation therapy, using a median dose of 60 Gy given in 30 fractions. After randomization, patients in the chemotherapy group also received (1) six weekly courses, administered during irradiation, of DBD 700 mg/m2 and (2) one to nine (median, four) courses, administered during the first year following radiation therapy, of DBD 1,000 mg/m2 on day 1 and BCNU 150 mg/m2 on day 2, with the course being repeated every 6 weeks.

Results: Patients treated with radiation therapy along with DBD plus BCNU (group 2) had significantly longer survival time (p = 0.044) and time to progression (p = 0.003) than did those treated with radiation therapy alone (group 1). The median survival time was 13.0 months for group 2 and 10.4 months for group 1; the median time to progression was 8.1 months for group 2 and 6.7 months for group 1. The percentage of patients alive at 18 and 24 months was 34% and 21% in group 2 compared with 21% and 12% in group 1.

Conclusion: DBD plus BCNU is an effective adjuvant therapy for malignant glioma.

Citing Articles

The efficacy of temozolomide combined with levetiracetam for glioblastoma (GBM) after surgery: a study protocol for a double-blinded and randomized controlled trial.

Sun M, Huang N, Tao Y, Wen R, Zhao G, Zhang X Trials. 2022; 23(1):234.

PMID: 35346332 PMC: 8962067. DOI: 10.1186/s13063-022-06168-1.


Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.

Hanna C, Lawrie T, Rogozinska E, Kernohan A, Jefferies S, Bulbeck H Cochrane Database Syst Rev. 2020; 3:CD013261.

PMID: 32202316 PMC: 7086476. DOI: 10.1002/14651858.CD013261.pub2.


The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.

Strowd R, Abuali I, Ye X, Lu Y, Grossman S J Neurooncol. 2016; 127(1):165-71.

PMID: 26729269 PMC: 4787612. DOI: 10.1007/s11060-015-2028-2.


Chemotherapy in glioma.

Taal W, Bromberg J, van den Bent M CNS Oncol. 2015; 4(3):179-92.

PMID: 25906059 PMC: 6088309. DOI: 10.2217/cns.15.2.


Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide.

Shonka N, Theeler B, Cahill D, Yung A, Smith L, Lei X J Neurooncol. 2013; 113(2):305-11.

PMID: 23526410 DOI: 10.1007/s11060-013-1116-4.